Metagen Therapeutics Announces Initial Closing of Series A, Introducing an Unprecedented Potential of Microbiome Therapeutics

Metagen Therapeutics (President and CEO: Taku Nakahara, PhD, MBA; Headquarters: Yamagata, Japan; hereinafter referred to as “MGTx”) has raised JPY 1.1 billion in the initial closing of its Series A as of April 2023. MGTx has been accelerating its drug discovery and development activities focused on intestinal microbiome-based therapeutics for a range of diseases. JIC Venture Growth Investments, a government-backed venture capital fund, has joined as a new investor, alongside existing investors Fast Track Initiative (hereinafter referred to as “FTI”), JAFCO Group, and Keio Innovation Initiative. FTI remains a VC BoD member.

This brings the total funds raised to JPY 1.33 billion, which MGTx plans to use to accelerate the establishment and operation of its proprietary microbiome bank, along with advancing research and development for its drug discovery programs toward the social implementation of Fecal Microbiota Transplantation (FMT).

FTI has supported MGTx since its foundation and continues to see progress in the company’s clinical research and solutions for the growing number of patients suffering from gastrointestinal diseases worldwide.

Click here for the official press release.  

About Metagen Therapeutics: Metagen Therapeutics (MGTx) is a university-launched venture business based out of Yamagata, Japan. The company was founded in 2020 with the mission of “continuing to fulfill the wishes of patients through microbiome science”. MGTx aims to create social impact through medical care and drug discovery based on intestinal microbiome research to address various gastrointestinal and immune system disorders. The company is led by top researchers in microbiome science from academic institutions Juntendo University, Tokyo Institute of Technology, and Keio University. For more information, go to https://www.metagentx.com or follow us on LinkedIn at https://www.linkedin.com/company/metagentx/. For press inquiries or investor inquiries, please email: pr@metagentx.com.   About Fast Track Initiative: Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on grow seed and early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including diagnostics, digital health, healthcare services, and more. The company provides full, hands-on operational support to its 30+ portfolio companies through business and R&D strategy, investor syndication, and more, including access to their exclusive network of leading industry professionals in Japan. Visit https://us.fasttrackinitiative.com  for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/. For press inquiries or investor inquiries, please email:  message.us@fasttrackinitiative.com